VEGF and bFGF plasma levels before and after 1 month of treatment with thalidomide.

Data are presented as individual values. VEGF plasma levels (panel A) decreased in 3 of 5 responding patients, whereas an increase was observed in 5 of 6 nonresponders (P = .197 for the comparison of change in VEGF between responders and nonresponders, Fisher exact test). The bFGF levels (panel B) declined in all responding patients and increased in 4 of 6 nonresponders (P = .045 for the comparison of change in bFGF between responders and nonresponders; Fisher exact test).